Proceedings of the dengue endgame summit: Imagining a world with dengue control

Adam D Wegman¹, Shirin Kalimuddin², Ernesto T A Marques³, Laura E Adams⁴, Alan L Rothman⁵, Gregory D Gromowski⁶, Taia T Wang⁷, Daniela Weiskopf⁸, Martin L Hibberd⁹, T Alex Perkins¹⁰, Rebecca C Christofferson¹¹, Bhagwat Gunale¹², Prasad S Kulkarni¹², Angel Rosas¹³, Louis Macareo¹⁴, Sophie Yacoub¹⁵, Eng Eong Ooi¹⁶, Gabriela Paz-Bailey⁴, Stephen J Thomas¹⁷, Adam T Waickman¹⁸

Affiliations

¹ Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
² Department of Infectious Diseases, Singapore General Hospital, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
³ Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA.
⁵ Department of Cell and Molecular Biology, Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA.
⁶ Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
⁷ Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA; Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
⁸ Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
⁹ London School of Hygiene & Tropical Medicine Department of Infection Biology, Keppel Street, London WC1E 7HT, England; Associate Faculty, National Institutes of Health, University of the Philippines, Philippines.
¹⁰ Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
¹¹ Department of Pathobiological Sciences, Louisiana School of Veterinary Medicine, Baton Rouge, LA, USA.
¹² Serum Institute of India Pvt. Ltd., Pune, India.
¹³ Takeda Pharmaceuticals, Inc, Boston, MA, USA.
¹⁴ Merck & Co., Inc., Rahway, NJ 07065, USA.
¹⁵ Oxford University Clinical Research Unit (OUCRU) Ho Chi Minh City, Viet Nam; Centre for Tropical Medicine and Global Health, University of Oxford, UK.
¹⁶ Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
¹⁷ Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: ThomStep@upstate.edu.
¹⁸ Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: waickmaa@upstate.edu.

PMID: 38890105
DOI: 10.1016/j.vaccine.2024.06.038

Proceedings of the dengue endgame summit: Imagining a world with dengue control

Adam D Wegman et al. Vaccine. 2024.

. 2024 Oct 3;42(23):126071.

doi: 10.1016/j.vaccine.2024.06.038. Epub 2024 Jun 17.

Authors

Affiliations

¹ Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
² Department of Infectious Diseases, Singapore General Hospital, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
³ Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA.
⁵ Department of Cell and Molecular Biology, Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA.
⁶ Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
⁷ Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA; Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
⁸ Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
⁹ London School of Hygiene & Tropical Medicine Department of Infection Biology, Keppel Street, London WC1E 7HT, England; Associate Faculty, National Institutes of Health, University of the Philippines, Philippines.
¹⁰ Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
¹¹ Department of Pathobiological Sciences, Louisiana School of Veterinary Medicine, Baton Rouge, LA, USA.
¹² Serum Institute of India Pvt. Ltd., Pune, India.
¹³ Takeda Pharmaceuticals, Inc, Boston, MA, USA.
¹⁴ Merck & Co., Inc., Rahway, NJ 07065, USA.
¹⁵ Oxford University Clinical Research Unit (OUCRU) Ho Chi Minh City, Viet Nam; Centre for Tropical Medicine and Global Health, University of Oxford, UK.
¹⁶ Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
¹⁷ Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: ThomStep@upstate.edu.
¹⁸ Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address: waickmaa@upstate.edu.

PMID: 38890105
DOI: 10.1016/j.vaccine.2024.06.038

Abstract

The first dengue "endgame" summit was held in Syracuse, NY over August 9 and 10, 2023. Organized and hosted by the Institute for Global Health and Translational Sciences at SUNY Upstate Medical University, the gathering brought together researchers, clinicians, drug and vaccine developers, government officials, and other key stakeholders in the dengue field for a highly collaborative and discussion-oriented event. The objective of the gathering was to discuss the current state of dengue around the world, what dengue "control" might look like, and what a potential roadmap might look like to achieve functional dengue control. Over the course of 7 sessions, speakers with a diverse array of expertise highlighted both current and historic challenges associated with dengue control, the state of dengue countermeasure development and deployment, as well as fundamental virologic, immunologic, and medical barriers to achieving dengue control. While sustained eradication of dengue was considered challenging, attendees were optimistic that significant reduction in the burden of dengue can be achieved by integration of vector control with effective application of therapeutics and vaccines.

Keywords: Dengue virus; Eradication; Therapy; Vaccine.

PubMed Disclaimer

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Proceedings of the dengue endgame summit: Imagining a world with dengue control

Affiliations

Proceedings of the dengue endgame summit: Imagining a world with dengue control

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical